Skip to main content
Top
Published in: Infection 6/2016

01-12-2016 | Original Paper

CAND-LO 2014–15 study: changing epidemiology of candidemia in Lombardy (Italy)

Authors: Anna Prigitano, Caterina Cavanna, Marco Passera, Cristina Ossi, Eugenio Sala, Gianluigi Lombardi, Anna Grancini, Concetta De Luca, Simone Bramati, Marina Gelmi, Milvana Tejada, Romualdo Grande, Claudio Farina, Fabiola Lallitto, Anna Maria Tortorano

Published in: Infection | Issue 6/2016

Login to get access

Abstract

Purpose

The aim of this study was to monitor recent changes in the epidemiology of candidemia and in the antifungal susceptibility profiles of Candida isolates in one Italian region (Lombardy) in 2014–2015 in comparison with two other studies performed in the same area in 1997–1999 and in 2009.

Methods

A laboratory-based surveillance was conducted in 11 microbiology laboratories. Identification of Candida isolates from 868 episodes and antifungal susceptibility testing (YeastOne) was performed locally.

Results

A progressive increase in the rate of candidemia up to 1.27/1000 admissions and 1.59/10,000 patient days was documented. In all the three surveys, Candida albicans remains the most frequently isolated species, ranging from 52 to 59 % of the etiology of BSIs. The epidemiological shift to the more resistant C. glabrata, observed between 1997–1999 and 2009 surveys, was not confirmed by our more recent data. The pattern of etiology of BSIs occurred in 2014–2015 overlaps that of the 90s. Acquired antifungal resistance is a rare event. No isolate had an amphoterin B minimal inhibitory concentration (MIC, mg/L) value higher than the epidemiological cutoff. All the echinocandin MIC distributions are typical for wild-type organisms except for those of two C. glabrata isolates. Fluconazole resistance declined from 24.9 % in the 2009 survey to 5.4 % in the recent one.

Conclusions

Data from regional surveys may highlight the influence of therapeutic practices on the epidemiology of Candida BSIs and may optimize empirical therapies.
Literature
1.
go back to reference Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients. Antimicrob Agents Chemother. 2011;55:532–8.CrossRefPubMed Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients. Antimicrob Agents Chemother. 2011;55:532–8.CrossRefPubMed
2.
go back to reference Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45–8.CrossRefPubMed Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45–8.CrossRefPubMed
3.
go back to reference Arendrup MC. Candida and candidaemia. Susceptibility and epidemiology. Dan Med J. 2013;60:B4698.PubMed Arendrup MC. Candida and candidaemia. Susceptibility and epidemiology. Dan Med J. 2013;60:B4698.PubMed
4.
go back to reference Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20:S5–10.CrossRef Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20:S5–10.CrossRef
5.
go back to reference Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidemia: report from one Italian region. J Hosp Infect. 2002;51:297–304.CrossRefPubMed Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidemia: report from one Italian region. J Hosp Infect. 2002;51:297–304.CrossRefPubMed
6.
go back to reference Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013;41:655–62.CrossRefPubMed Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013;41:655–62.CrossRefPubMed
7.
go back to reference Cantón E, Pemán J, Hervás D, Iñiguez C, Navarro D, Echeverría J, et al. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric sensititre YeastOne method. J Clin Microbiol. 2012;50:3921–6.CrossRefPubMedPubMedCentral Cantón E, Pemán J, Hervás D, Iñiguez C, Navarro D, Echeverría J, et al. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric sensititre YeastOne method. J Clin Microbiol. 2012;50:3921–6.CrossRefPubMedPubMedCentral
8.
go back to reference Tadec L, Talarmin JP, Gastinne T, Bretonnière C, Miegeville M, Le Pape P, et al. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital: a 7-year study. Mycoses. 2016;59:296–303.CrossRefPubMed Tadec L, Talarmin JP, Gastinne T, Bretonnière C, Miegeville M, Le Pape P, et al. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital: a 7-year study. Mycoses. 2016;59:296–303.CrossRefPubMed
9.
go back to reference Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19:E343–53.CrossRefPubMed Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19:E343–53.CrossRefPubMed
10.
go back to reference Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol. 2013;51:4167–72.CrossRefPubMedPubMedCentral Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol. 2013;51:4167–72.CrossRefPubMedPubMedCentral
11.
go back to reference Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB, et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43:78–81.CrossRefPubMed Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB, et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43:78–81.CrossRefPubMed
12.
go back to reference Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the sentry antimicrobial surveillance program, 2008–2009. Antimicrob Agents Chemother. 2011;55:561–6.CrossRefPubMed Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the sentry antimicrobial surveillance program, 2008–2009. Antimicrob Agents Chemother. 2011;55:561–6.CrossRefPubMed
13.
go back to reference Fekkar A, Dannaoui E, Meyer I, Imbert S, Brossas JY, Uzunov M, et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis. 2014;33:1489–96.CrossRefPubMed Fekkar A, Dannaoui E, Meyer I, Imbert S, Brossas JY, Uzunov M, et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis. 2014;33:1489–96.CrossRefPubMed
Metadata
Title
CAND-LO 2014–15 study: changing epidemiology of candidemia in Lombardy (Italy)
Authors
Anna Prigitano
Caterina Cavanna
Marco Passera
Cristina Ossi
Eugenio Sala
Gianluigi Lombardi
Anna Grancini
Concetta De Luca
Simone Bramati
Marina Gelmi
Milvana Tejada
Romualdo Grande
Claudio Farina
Fabiola Lallitto
Anna Maria Tortorano
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-016-0951-6

Other articles of this Issue 6/2016

Infection 6/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.